| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 05/11/2005 | CN1200702C Use of NMDA antagonist for treatment of irritable bowel syndrome |
| 05/11/2005 | CN1200701C Compositions for reducing incidence of necrotizing enterocolitis |
| 05/11/2005 | CN1200700C Pharmaceutical tramadol salts |
| 05/11/2005 | CN1200684C Compositions comprising organosiloxane resins for delivering oral care substances |
| 05/11/2005 | CN1200654C Method and device for preparing dental implant by immersion in mesenchymal cell culture |
| 05/10/2005 | US6890961 Applying topically to the leukoplakia lesion an effective amount of a clear aqueous formulation comprising: water; a water miscible polyol; unsaturated fatty acid ester; a surfactant, and beta -carotene |
| 05/10/2005 | US6890959 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea |
| 05/10/2005 | US6890952 Administering cyclic substituted aminomethyl compounds for the preparation of a drug for the treatment of pain, urinary incotinence, itching, tinnitus aurium or diarrhea in a mammal |
| 05/10/2005 | US6890938 Antiinflammatory agents |
| 05/10/2005 | US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1 |
| 05/10/2005 | US6890935 Pharmaceutical compositions and methods for use |
| 05/10/2005 | US6890929 Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease |
| 05/10/2005 | US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890900 Methods for treating or preventing diseases of the oral cavity |
| 05/10/2005 | US6890549 Reducing levels of bioavailable fat by adminstering alpha-cyclodextrin |
| 05/10/2005 | US6890547 Glycyrrhizin preparations for transmucosal absorption |
| 05/10/2005 | US6890523 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarreah agents |
| 05/10/2005 | CA2330935C A mutant human hepatitis b viral strain and uses thereof |
| 05/10/2005 | CA2116192C Highly concentrated tcf pharmaceutical preparations |
| 05/06/2005 | WO2005040218A1 METHOD FOR PREPARING COMPOSITE IgY SPECIFIC AGAINST PERIODONTAL DISEASE AND COMPOSITE PREPARATION THEREOF |
| 05/06/2005 | WO2005040108A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors |
| 05/06/2005 | WO2005039609A2 Moderating the effect of endotoxins |
| 05/06/2005 | WO2005039607A1 The use of balloonfish collagen i extractive in medical care and the preparative method of it |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039599A1 Matrix metalloprotease inhibitor containing polylactic acid mixture |
| 05/06/2005 | WO2005039589A2 Cftr channel modulators |
| 05/06/2005 | WO2005039581A1 Use of estrogen receptor ligands for the treatment of inflammatory bowel disease |
| 05/06/2005 | WO2004096218A3 Pellet formulations of acid-labile antiulcer benzimidazole compounds |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | CA2542452A1 Moderating the effect of endotoxins |
| 05/06/2005 | CA2542448A1 Moderating the effect of endotoxins |
| 05/06/2005 | CA2541991A1 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds |
| 05/06/2005 | CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these |
| 05/06/2005 | CA2526804A1 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096397 Adding trifluoroacetic acid dropwise to a solution of dimethylphenylsilane and (S)-amino-1-(2,5-dimethoxy-phenyl)-1-propanone, the amino group of which is protected, for example, with a methoxycarbonyl group; reduction; deprotecting; salt formation |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096378 Fundic relaxation; dyspepsia, early satiety, bloating and anorexia; 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl- )methyl]amino]-2-hydroxypropyl]-2,4-imidazolidinedione |
| 05/05/2005 | US20050096359 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride |
| 05/05/2005 | US20050096348 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096271 Fusion of polypeptides and immunoglobulin protein; immunotherapy ; antiallergens; antiarthritic agents; anticancer agents; antiinflammatory agents |
| 05/05/2005 | US20050096268 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/05/2005 | US20050096262 Helicobacter pylori adhesion inhibitor |
| 05/05/2005 | US20050095703 Generating progenitor cells for use in prevention and treatment of cell proliferative, neurodegenerative and pancreatic disorders; regenerative medicine; tissue engineering |
| 05/05/2005 | US20050095584 Method for determining early HCV seroconversion |
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095285 Pharmaceutical composition and a process for its preparation |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |
| 05/05/2005 | US20050095238 Treating a disease associated with leukocyte infiltration of mucosal tissues, such as inflammatory bowel disease, asthma, graft vs host disease, pancreatitis, diabetes, or sinutitis with a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin |
| 05/05/2005 | US20050095224 Compositions and method for treating hepatitis virus infection |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527343A2 Organic compounds |
| 05/04/2005 | EP1527178A2 Novel class ii cytokine receptors and uses thereof |
| 05/04/2005 | EP1527159A1 Probiotic propionibacterium jensenii 702 |
| 05/04/2005 | EP1527075A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
| 05/04/2005 | EP1527070A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 05/04/2005 | EP1527068A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 05/04/2005 | EP1527063A1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/04/2005 | EP1527062A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 05/04/2005 | EP1527051A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 05/04/2005 | EP1527046A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 05/04/2005 | EP1526895A2 Methods for treating carbonic anhydrase mediated disorders |
| 05/04/2005 | EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 05/04/2005 | EP1526864A2 Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip) |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1411881B1 5ht2c receptor modulators |
| 05/04/2005 | EP1395582B1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same |
| 05/04/2005 | EP1377164A4 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 05/04/2005 | EP1362048B1 Triazolo compounds as mmp inhibitors |
| 05/04/2005 | EP1341539B1 Anti-inflammatory agents |
| 05/04/2005 | EP1317448B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/04/2005 | EP1259477B1 Aminoadamantane derivatives as therapeutic agents |
| 05/04/2005 | EP1246790B1 Substituted 1 and 2 naphthol mannich bases |
| 05/04/2005 | EP1240165B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 05/04/2005 | EP1185292B1 Use of interleukin-11 to treat hemorrhagic shock |
| 05/04/2005 | EP1086117A4 Cloning and identification of the motilin receptor |
| 05/04/2005 | EP0825858B1 Time-dependant release capsules containing omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease |
| 05/04/2005 | CN1612877A Spiroazacyclic compounds as monoamine receptor modulators |
| 05/04/2005 | CN1612864A Novel alkansulfonamides as endothelin antagonists |
| 05/04/2005 | CN1612852A Lipoxin A4 analogs |
| 05/04/2005 | CN1612745A Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 05/04/2005 | CN1612743A Herbal composition phy906 and its use in chemotheraphy |
| 05/04/2005 | CN1612739A Method for treating or preventing inflammatory diseases |
| 05/04/2005 | CN1612733A Benzimidazoles useful as protein kinase inhibitors |
| 05/04/2005 | CN1612731A Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 05/04/2005 | CN1612729A 2-aryl-propionic acid and medicine composition containing same |
| 05/04/2005 | CN1611260A Combined medicine of adefovir dipivoxil |
| 05/04/2005 | CN1611257A Childreu-care digestive capsule and its preparing method |
| 05/04/2005 | CN1611249A Antisenescent longevity powder |